Plasma volume expansion agents

Special Precautions Hypoglycemia in combination with insulin or oral hypoglycemic agents Pregnancy Category C Ovulation Decreases in hemoglobulin and hematocrit Idiosyncratic hepatoxicity Edema Plasma volume expansion and pre-load-induced cardiac... 

After Ed s move to Einstein in 1956, a joint U.S. patent in the public interests was filed (together with H. M. Tsuchiya and N. N. Heilman) on the practical production of the Streptococcus DS-50 dextran. Pilot plant production was undertaken at NRRL clean-up and bottling were carried out as a service by the Cutter Corp. and a successful clinical trial of the dextran for treatment of patients in shock was conducted by Dr. W. Metcalf of Einstein s Department of Surgery. Ed presented a final report to the National Research Council in 1962. In the end, despite the discovery of a simpler way to manufacture a product of great potential military usefulness, dextran in general would be replaced by blood and plasma as agents of plasma volume expansion in shock patients. 

---